Results 41 to 50 of about 676,789 (144)

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice

Cells
The programmed cell death protein 1 (PD-1) plays a critical role in cancer immune evasion. Blocking the PD-1-PD-L1 interaction by monoclonal antibodies has shown remarkable clinical efficacy in treating certain types of cancer.
Shanshan (Jenny) Zhong, Xiaoling Liu, Tomonori Kaneko, Yan Feng, Owen Hovey, Kyle Yang, Sally Ezra, Soon-Duck Ha, Sung Kim, John K. McCormick, Huadong Liu, Shawn Shun-Cheng Li   +11 more
doaj   +1 more source

Assays for predicting and monitoring responses to lung cancer immunotherapy

Cancer Biology & Medicine, 2015
Immunotherapy has become a key strategy for cancer treatment, and two immune checkpoints, namely, programmed cell death 1 (PD-1) and its ligand (PD-L1), have recently emerged as important targets.
Cristina Teixidó, Niki Karachaliou, Maria González-Cao, Daniela Morales-Espinosa, Rafael Rosell   +4 more
doaj   +1 more source

Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non‐small cell lung cancer: Chinese multicenter report and literature review

Thoracic Cancer, 2020
Background The PACIFIC study has defined a new standard of care for patients with unresectable stage III non‐small cell lung cancer (NSCLC) in the form of immune checkpoint inhibitor (ICI) consolidation therapy.
Tao Zhang, Kunpeng Xu, Nan Bi, Li Zhang, Wei Jiang, Jun Liang, Lei Deng, Xin Wang, Jianyang Wang, Jie Wang, Luhua Wang   +10 more
doaj   +1 more source

The clinical importance of PD‑L1 and PD‑1 expression in diffuse large B cell lymphoma [PDF]

Archives of the Balkan Medical Union, 2018
Introduction. The target pathway programmed cell death‑1 (PD‑1)/ programmed death‑ligand 1 (PD‑L1) shows clinical efficacy in solid tumors, but also in Hodgkin’s and non‑Hodgkin’s lymphoma. PD‑L1 expression most often correlates with a poor prognosis and
Adelina BIRCEANU COROBEA, Anca EVSEI, Cristian ROSIANU, Mircea GHEORGHE, Gabriela BIRCEANU, Maria SAJIN , Anca LUPU , Narcis COPCA   +7 more
doaj   +1 more source

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy

Cancer Biology & Medicine, 2018
Cancer immunotherapy has greatly advanced in recent years, and PD-1/PD-L1 blocking therapy has become a major pillar of immunotherapy. Successful clinical trials of PD-1/PD-L1 blocking therapies in cancer treatments have benefited many patients, which ...
Long Jia, Qi Zhang, Rongxin Zhang
doaj   +1 more source

PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

Nature Immunology, 2019
Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1) is crucial for the development of reversal strategies. In anti-PD-1-resistant models, simultaneous anti-PD-1 and vaccine therapy reversed resistance, while PD-1 blockade before antigen priming abolished therapeutic outcomes.
Vivek Verma, Rajeev K Shrimali, Shamim Ahmad, Winjie Dai, Hua Wang, Sumin Lu, Rahul Nandre, Pankaj Gaur, Jose Lopez, Moshe Sade-Feldman, Keren Yizhak, Stacey L. Bjorgaard, Keith T. Flaherty, Jennifer A. Wargo, Genevieve M. Boland, Ryan J. Sullivan, Gad Getz, Scott A. Hammond, Ming Tan, Jingjing Qi, Phillip Wong, Taha Merghoub, Jedd Wolchok, Nir Hacohen, John E. Janik, Mikayel Mkrtichyan, Seema Gupta, Samir N. Khleif   +27 more
openaire   +3 more sources

Optimum fractionation of radiation to combine PD‐1 blockade

MedComm, 2023
The optimum fractionation of radiation to combine with immune checkpoint blockade is controversial. This study aimed to investigate the fractionated radiation to maximize immunity during combination therapy. To evaluate the abscopal effect, C57BL/6 hPD‐1
Feifei Teng, Tianwen Yin, Xiao Ju, Peiliang Wang, Yungang Wang, Jinming Yu   +5 more
doaj   +1 more source

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages

Journal of Inflammation Research, 2021
Chun-Yi Lai,1,2,* Po-Chun Tseng,1,2,* Chia-Ling Chen,3 Rahmat Dani Satria,2,4– 6 Yung-Ting Wang,2 Chiou-Feng Lin1,2,7,8 1Core Laboratory of Immune Monitoring, Office of Research & Development, Taipei Medical University, Taipei, 110, Taiwan ...
Lai CY, Tseng PC, Chen CL, Satria RD, Wang YT, Lin CF   +5 more
doaj  

PD-1/PD-L1 Inhibitors in Cervical Cancer

Frontiers in Pharmacology, 2019
Cervical cancer is one of the most common gynecological tumors, and the majority of early-stage cervical cancer patients achieve good recovery through surgical treatment and concurrent chemoradiotherapy (CCRT).
Yuncong Liu, Yuncong Liu, Li Wu, Ruizhan Tong, Feiyue Yang, Limei Yin, Limei Yin, Mengqian Li, Mengqian Li, Liting You, Liting You, Jianxin Xue, Jianxin Xue, You Lu, You Lu   +14 more
doaj   +1 more source

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution

Frontiers in Immunology
Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule until recently believed to exist only in tetrapod species. However, together with a very recent study dedicated to the CD28/CTLA4 molecule family, this study—using database ...
Ryohei Kondo, Kohei Kondo, Kei Nabeshima, Akihiko Nishikimi, Yasumasa Ishida, Toshiaki Shigeoka, Johannes M. Dijkstra   +6 more
doaj   +1 more source